Interleukin-2 for the treatment of melanoma

Current Opinion in Investigational Drugs

Volumn 6, Issue 12, 2005, Pages 1234-1239

  Tarhini, Ahmad A ^a   Agarwala, Sanjiv S ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Biochemotherapy; IL 2; Immunotherapy; Lymphokine activated killer cells; Melanoma; Tumor infiltrating lymphocytes

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CANCER VACCINE; CARMUSTINE; CISPLATIN; DACARBAZINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTAMINE; INTERLEUKIN 2; MANGANESEDICHLORO(3,10,13,20,26 PENTAAZATETRACYCLO[20.3.1.0(4,9).0(14,19)] 1(26),22(23),24 HEXACOSATRIENE); VINBLASTINE;

ADOPTIVE IMMUNOTHERAPY; ADVANCED CANCER; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CHILL; CLINICAL TRIAL; COGNITIVE DEFECT; CONTINUOUS INFUSION; DELUSION; DISORIENTATION; DRUG FEVER; DRUG MEGADOSE; DRUG STRUCTURE; EDEMA; HALLUCINATION; HUMAN; HYPOTENSION; HYPOXIA; IMMUNE SYSTEM; KIDNEY FAILURE; LUNG CONGESTION; LYMPHOKINE ACTIVATED KILLER CELL; MALAISE; MELANOMA; METASTASIS POTENTIAL; NEUROTOXICITY; NONHUMAN; OLIGURIA; OUTPATIENT; REVIEW; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; TUMOR ASSOCIATED LEUKOCYTE; UNITED STATES; VIRAL GENE THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; GENE THERAPY; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; MELANOMA; RANDOMIZED CONTROLLED TRIALS;

EID: 29444456949     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics, 2005. CA Cancer J Clin (2005) 55(1):10-30.
2. Millward MJ, Bedikian AY, Conry RM, Gore ME, Pehamberger HE, Stery W, Pavlick AC, De Conti RC, Gordon D, Itri LM: Randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM): Analysis of long-term survival. Proc Am Soc Clin Oncol (2004) 23:Abs 7505.
3. Agarwala SS, Ferri W, Gooding W, Kirkwood JM: A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer (1999) 85(9):1979-1984.
4. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 17(9):2745-2751.
5. Morgan DA, Ruscetti FW, Gallo R: Selective in vitro growth of T lymphocytes from normal human bone marrows. Science (1976) 193(4257):1007-1008.
6. Taniguchi T, Matsui H, Fujita T, Takaoka C, Kashima N, Yoshimoto R, Hamuro J: Structure and expression of a cloned cDNA for human interleukin-2. Nature (1983) 302(5906):305-310.
7. Smith KA: Interleukin-2: Inception, impact, and implications. Science (1988) 240(4856):1169-1176.
8. Granucci F, Vizzardelli C, Pavelka N, Feau S, Persico M, Virzi E, Rescigno M, Moro G, Ricciardi-Castagnoli P: Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nat Immunol (2001) 2(9):882-888.
9. Bassiri H, Carding SR: A requirement for IL-2/IL-2 receptor signaling in intrathymic negative selection. J Immunol (2001) 166(10):5945-5954.
10. Mosmann TR, Sad S: The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today (1996) 17(3):138-146.
11. Schorle H, Holtschke T, Hunig T, Schimpl A, Horak I: Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature (1991) 352(6336):621-624.
12. Malek TR: The main function of IL-2 is to promote the development of T regulatory cells. J Leukocyte Biol (2003) 74(6):961-965.
13. Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL: Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration at high-dose recombinant interleukin 2. J Exp Med (1985) 161(5):1169-1188.
14. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA: Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med (1982) 155(6):1823-1841.
15. Grimm EA, Robb RJ, Roth JA, Neckers LM, Lachman LB, Wilson DJ, Rosenberg SA: Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. J Exp Med (1983) 158(4):1356-1361.
16. Lafreniere R, Rosenberg SA: Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. J Immunol (1985) 135(6):4273-4280.
17. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med (1987) 316(15):889-897.
18. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst (1993) 85(8):622-632.
19. Figlin RA, Thompson JA, Bukowski RM, Vogelzang NJ, Novick AC, Lange P, Steinberg GD, Belldegrun AS: Multicenter, randomized, phase III trial of CD8+ tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol (1999) 17(8):2521-2529.
20. Dutcher JP, Creekmore S, Weiss GR, Margolin K, Markowitz AB, Roper M, Parkinson D, Ciobanu N, Fisher RI, Boldt DH: A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol (1989) 7(4):477-485.
21. Parkinson DR, Abrams JS, Wiernik PH, Rayner AA, Margolin KA, Van Echo DA, Sznol M, Dutcher JP, Aronson FR, Doroshow JH: Interleukin-2 therapy in patients with metastatic malignant melanoma: A phase II study. J Clin Oncol (1990) 8(10):1650-1656.
22. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhom JH, White DE: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. J Am Med Assoc (1994) 271(12):907-913.
23. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C et al: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 17(7):2105-2116.
24. Atkins MB, Kunkel L, Sznol M, Rosenberg SA: High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update. Cancer J Sci Am (2000) 6(Suppl 1):S11-S14.
25. Agarwala SS, Stover LL: The University of Pittsburgh Cancer Institute; Experience with interleukin-2 (IL-2) in the treatment of melanoma. Immune Enhancing Cytokines (2001) 3:3-7.
26. Schwartzentruber DJ: High-dose interleukin-2 is an intensive treatment regardless of the venue of administration. Cancer J (2001) 7(2):103-104.
27. West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK: Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med (1987) 316(15):898-905.
28. Dillman RO, Church C, Oldham RK, West WH, Schwartzberg L, Birch R: Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience. Cancer (1993) 71(7):2358-2370.
29. Legha SS, Gianan MA, Plager C, Eton OE, Papadopoulous NE: Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. Cancer (1996) 77(1):89-96.
30. Dillman RO, Church C, Barth NM, Oldham RK, Wiemann MC: Long-term survival after continuous infusion interleukin-2. Cancer Biother Radiopharm (1997) 12(4):243-248.
31. Agarwala SS, Glaspy J, O'Day SJ, Mitchell M, Gutheil J, Whitman E, Gonzalez R, Hersh E, Feun L, Belt R, Meyskens F et al: Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol (2002) 20(1):125-133.
32. Hansson M, Asea A, Ersson U, Hermodsson S, Hellstrand K: Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. J Immunol (1996) 156(1):42-47.
33. Hansson M, Asea A, Hermodsson S, Hellstrand K: Histaminergic regulation of NK-cells: Protection against monocyte-induced apoptosis. Scand J Immunol (1996) 44(2):193-196.
34. Hansson M, Hermodsson S, Brune M, Mellqvist UH, Naredi P, Betten A, Gehlsen KR, Hellstrand K: Histamine protects T cells and natural killer cells against oxidative stress. J Interferon Cytokine Res (1999) 19(10):1135-1144.
35. Hellstrand K, Brune M, Naredi P, Mellqvist UH, Hansson M, Gehlsen KR, Hermodsson S: Histamine: A novel approach to cancer immunotherapy. Cancer Invest (2000) 18(4):347-355.
36. Flaherty LE, Atkins M, Sosman J, Weiss G, Clark JI, Margolin K, Dutcher J, Gordon MS, Lotze M, Mier J, Sorokin P et al: Outpatient biochemotherapy with interleukin-2 and interferon α-2b in patients with metastatic malignant melanoma: Results of two phase II cytokine working group trials. J Clin Oncol (2001) 19(13):3194-3202.
37. Rosenberg SA, Schwarz SL, Spiess PJ: Combination immunotherapy for cancer: Synergistic antitumor interactions of interleukin-2, α-interferon, and tumor-infiltrating lymphocytes. J Natl Cancer Inst (1988) 80(17):1393-1397.
38. Cameron RB, McIntosh JK, Rosenberg SA: Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid α-interferon in the treatment of established murine hepatic metastases. Cancer Res (1988) 48(20):5810-5817.
39. Rosenberg SA, Lotze MT, Yang JC, Linehan WM, Seipp C, Calabro S, Karp SE, Sherry RM, Steinberg S, White DE: Combination therapy with interleukin-2 and α-interferon for the treatment of patients with advanced cancer. J Glin Oncol (1989) 7(12):1863-1874.
40. Marincola FM, White DE, Wise AP, Rosenberg SA: Combination therapy with interferon α-2a and interleukin-2 for the treatment of metastatic cancer. J Clin Oncol (1995) 13(5):1110-1122.
41. Keilholz U, Scheibenbogen C, Tilgen W, Bergmann L, Weidmann E, Seither E, Richter M, Brado B, Mitrou PS, Hunstein W: Interfaron-α and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials. Cancer (1993) 72(2):607-614.
42. Karp SE: Low-dose intravenous bolus interleukin-2 with interferon-α therapy for metastatic melanoma and renal cell carcinoma. J Immunother (1998) 21(1):56-61.
43. Sparano JA, Fisher RI, Sunderland M, Margolin K, Ernest ML, Sznol M, Atkins MB, Dutcher JP, Micetich KC, Weiss GR: Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon α-2a in patients with advanced melanoma. J Clin Oncol (1993) 11(10):1969-1977.
44. Atkins MB, O'Boyle KR, Sosman JA, Weiss GR, Margolin KA, Ernest ML, Kappler K, Mier JW, Sparano JA, Fisher RI: Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol (1994) 12(8):1553-1560.
45. Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, Papadopoulos N: Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon α, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol (1998) 16(5):1752-1759.
46. Richards JM, Mehta N, Ramming K, Skosey P: Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol (1992) 10(8):1338-1343.
47. Antoine EC, Benhammouda A, Bernard A, Youssef A, Mortier N, Gozy M, Nizri D, Auclerc G, Rocher MA, Soubrane CL, Weil M, Khayat D: Salpetriere Hospital experience with biochemotherapy in metastatic melanoma. Cancer J Sci Am (1997) 3(Suppl 1):S16-S21.
48. Demchak PA, Mier JW, Robert NJ, O'Brien K, Gould JA, Atkins MB: Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: A pilot study. J Clin Oncol (1991) 9(10):1821-1830.
49. Keilholz U, Stoter G, Punt CJ, Scheibenbogen C, Lejeune F, Eggermont AM: Recombinant interleukin-2-based treatments for advanced melanoma: The experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. Cancer J Sci Am (1997) 3(Suppl 1):S22-S28.
50. Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS: Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial. J Clin Oncol (2002) 20(8):2045-2052.
51. McDermott DF, Mier JW, Lawrence DP, van den Brink MR, Clancy MA, Rubin KM, Atkins MB: A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon α-2B in patients with metastatic melanoma. Clin Cancer Res (2000) 6(6):2201-2208.
52. Atkins MB, Lee S, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM: A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon α-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): An ECOG-coordinated intergroup trial. Proc Am Soc Clin Oncol (2003) 22:Abs 2847.
53. Del Vecchio M, Bajetta E, Vitali M, Gattinoni L, Santinami M, Daponte A, Sertoli MR, Queirolo P, Bemengo MG, Cascinelli N: Multicenter phase III randomized trial of cisplatin, vindesine and dacarbazine (CVD) versus CVD plus subcutaneous (sc) interleukin-2 (IL-2) and interferon-α-2b (IFN) in metastatic melanoma patients (pts). Proc Am Soc Clin Oncol (2003) 22:Abs 2849.
54. Keilholz U, Punt CJ, Gore M, Suciu S, Kruit W, Patel P, Lienard D, Thomas J, Lehmann F, Eggermont AM: Dacarbazine, cisplatin and IFN-α2b with or without IL-2 in advanced melanoma: Final analysis of EORTC randomized phase III trial 18951. Proc Am Soc Clin Oncol (2003) 22:Abs 2848.
55. O'Day SJ, Boasberg PD, Piro L, Kristedja TS, Wang HJ, Martin M, Deck R, Ames P, Shinn K, Kim H, Fournier P, Gammon G: Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin Cancer Res (2002) 8(9):2775-2781.
56. Flaherty LE, Robinson W, Redman BG, Gonzalez R, Martino S, Kraut M, Valdivieso M, Rudolph AR: A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma. Cancer (1993) 71(11):3520-3525.
57. Atzpodien J, Lopez Hanninen E, Kirchner H, Franzke A, Korfer A, Volkenandt M, Duensing S, Schomburg A, Chaitchik S, Poliwoda H: Chemoimmunotherapy of advanced malignant melanoma: Sequential administration of subcutaneous interleukin-2 and interferon-α after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. Eur J Cancer (1995) 31A(6):876-881.
58. Thompson JA, Gold PJ, Markowitz DR, Byrd DR, Lindgren CG, Fefer A: Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma. Cancer J Sci Am (1997) 3(Supp] 1):S29-S34.
59. Liu K, Rosenberg SA: Interleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependent. J Immunother (2003) 26(3):190-201.
60. Hauschild A, Weichenthal M, Balda BR, Becker JC, Wolff HH, Tilgen W, Schulte KW, Ring J, Schadendorf D, Lischner S, Burg G, Dummer R: Prospective randomized trial of interferon α-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol (2003) 21(15):2883-2888.
61. Chemotherapy plus biological therapy in treating patients with melanoma. National Cancer Institute, Bethesda, MD, USA (2005). http://www. clinicaltrials.gov/ct/gui/show/NCT00006237
62. Margolin K, Atkins M, Sparano J, Sosman J, Weiss G, Lotze M, Doroshow J, Mier J, O'Boyle K, Fisher R, Campbell E et al: Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma. Clin Cancer Res (1997) 3(4):565-572.
63. Du Bois JS, Trehu EG, Mier JW, Shapiro L, Epstein M, Klempner M, Dinarello C, Kappler K, Ronayne L, Rand W, Atkins MB: Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J Clin Oncol (1997) 15(3):1052-1062.
64. Samlowski WE, Petersen R, Cuzzocrea S, Macarthur H, Burton D, McGregor JR, Salvemini D: A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects. Nat Med (2003) 9(6):750-755.
65. Schwartzentruber DJ: Guidelines for the safe administration of high-dose interleukin-2. J Immunother (2001) 24(4):287-293.
66. Kammula US, White DE, Rosenberg SA: Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer (1998) 83(4):797-805.